A new MSS-CRC PD-1 combo trial announced = "NKTR-214". No NCT# yet just press release. In preclinical CRC models they saw activity of single agent - but as usual, my guess (but just a guess) is that clinically - a combo with PD1 is more likely to be successful.
Trial announcement:
http://investor.bms.com/investors/news- ... fault.aspx
ASCO-2016 Preclinical Data in CRC (press release):
http://ir.nektar.com/releasedetail.cfm?ReleaseID=974493
Single agent trial still in progress (CT, OR, TX):
NCT02869295
https://clinicaltrials.gov/ct2/show/NCT ... 214&rank=1
As an aside: As I completely expected, since the Cobi/Atezo "Proof of concept" we are now going to be overrun with new MSS-CRC combo trials to choose from over the next 12 months, today is just the latest example. On one level a good thing (many choices) but also an issue since how do you choose? But still a better situation than a year ago when MSS-CRC immunotherapy trial options were tough to find and doing any immunotherapy trial for MSS-CRC was not easy since demand outstripped supply of slots...
-DK37